BeiGene gets approval to transit from Biotech chapter of HKEX to a General Listing
BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following its application to the Stock Exchange of Hong Kong Limited (HKEX), the Company has been approved for listing under Rule 8.05(3) as a company that meets specified revenue and market capitalization thresholds. BeiGene initially listed on the HKEX on August 8, 2018 under the biotech chapter (Chapter 18A) of the Listing Rules. The Company now satisfies the revenue and market capitalization tests for listing outside of the biotech chapter. As a result of the approval, the “B” marker will be removed from the Company’s stock symbol in the HKEX, and the Company’s ordinary shares may become eligible for listing in the Hang Seng indices.
“We are pleased to become the first company listed on HKEX through the pre-revenue biotech chapter to transition into a general listing as a result of substantial revenues generated from our commercial portfolio. We are excited about the expected upcoming approvals and launches of zanubrutinib and tislelizumab to generate additional revenue opportunities and further our growth as a biotech company,” said John Oyler, Co-Founder, Chairman and Chief Executive Officer of BeiGene. “One of our goals for listing on the HKEX has been to access a broader investor base, and with this approval we are making progress toward this goal.